Literature DB >> 8843204

Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users.

D L Thomas1, J W Shih, H J Alter, D Vlahov, S Cohn, D R Hoover, L Cheung, K E Nelson.   

Abstract

To assess the effect of human immunodeficiency virus (HIV) immunosuppression on ongoing hepatitis C virus (HCV) infection, CD4 lymphocyte counts and serum concentrations of HCV RNA, HIV RNA, and alanine aminotransferase (ALT) were evaluated among members of a cohort of injecting drug users (IDUs). With 100 participants randomly selected at various stages of HIV-related immunosuppression, serum HCV RNA concentrations increased with age (P = .007) and were higher in HIV-positive IDUs with 201-500 (P = .026) and 51-200 (P = .004) CD4 cells/mL than in HIV-negative participants. Among 27 HCV-infected IDUs who acquired HIV infection, serum HCV RNA concentrations varied between semiannual visits by a mean of 0.45 logs, increasing by 0.60 logs after HIV seroconversion (P < .0001), by 0.12 logs each subsequent year (P = .006), and by 0.36 logs per log increase in CD4 cells (P = .01). Serum ALT levels were similar between HIV-positive (40.1 IU/mL) and HIV-negative (45.4 IU/mL) patients (P > .10). While HIV infection and possibly HIV progression are associated with increased HCV RNA levels, other factors appear to affect biochemical and virologic markers of HCV infection in some dually infected persons.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8843204     DOI: 10.1093/infdis/174.4.690

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  59 in total

Review 1.  Reciprocal interaction of human immunodeficiency virus and hepatitis C virus infections.

Authors:  K E Nelson; D L Thomas
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

2.  Current Views on Hepatitis C Virus Infection.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-02       Impact factor: 3.725

3.  Screening for hepatitis C virus in human immunodeficiency virus-infected individuals.

Authors:  C L Thio; K R Nolt; J Astemborski; D Vlahov; K E Nelson; D L Thomas
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

4.  2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus.

Authors: 
Journal:  Infect Dis Obstet Gynecol       Date:  2002

Review 5.  Opioids and HIV/HCV infection.

Authors:  Xu Wang; Ting Zhang; Wen-Zhe Ho
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-14       Impact factor: 4.147

6.  Human immunodeficiency virus seroconversion and evolution of the hepatitis C virus quasispecies.

Authors:  Q Mao; S C Ray; O Laeyendecker; J R Ticehurst; S A Strathdee; D Vlahov; D L Thomas
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

7.  Hepatitis C and HIV-1 coinfection.

Authors:  A H Mohsen; P Easterbrook; C B Taylor; S Norris
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

Review 8.  Hepatitis C virus infection in children coinfected with HIV: epidemiology and management.

Authors:  Massimo Resti; Chiara Azzari; Flavia Bortolotti
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

9.  Anti-HCV antibody among newly diagnosed HIV patients in Ughelli, a suburban area of Delta State Nigeria.

Authors:  Ogbodo Ekene Newton; Otue Akpevwe Oghene; Iheanyi Omezuruike Okonko
Journal:  Afr Health Sci       Date:  2015-09       Impact factor: 0.927

10.  Hepatitis C virus (HCV) core antigen assay to detect ongoing HCV infection in thai injection drug users.

Authors:  Dale M Netski; Xiao-Hong Wang; Shruti H Mehta; Kenrad Nelson; David Celentano; Satawat Thongsawat; Niwat Maneekarn; Vinai Suriyanon; Jaroon Jittiwutikorn; David L Thomas; John R Ticehurst
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.